Chief Scientific Officer and Head of the Scientific Management Area at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona (Spain). My tasks at VHIO include: Scientific support to the Director and strategic decisions on research activities; writing, coordination and management of scientific proposals; monitoring and evaluation of existing scientific & institutional programs; identification of competitive research funds/ opportunities and international research consortia. Member of VHIO’s Internal Scientific Committee and evaluator of national/ international research Calls. Master’s in management of R, D & I in Health Sciences. Previously worked in Translational Cancer Drugs Pharma (biotech company) and Mensor (Research Department). In terms of academic training: I graduated in Veterinary Science (Complutense University of Madrid) and hold a PhD cum laude in Biochemistry and Molecular Biology (Pasteur Institute and Denis Diderot University, Paris). I have also completed a post-doctoral stay (Juan de la Cierva Program) at the National Center for Biotechnology (Madrid), focused on the design of new viral vaccines.

Main 5 articles co-authored in last 5 years (2018-2022), include: (1) RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. Nat Med. 2022 Oct;28(10):2162-2170; (2) ERANET JTC 2011: Submission and Activation of an International Academic
Translational Project in Advanced Breast Cancer. Experience from the ET-FES Study. Monti M et al. Front Med (Lausanne). 2022 Jan 13;8:817678; (3) Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Tamborero D et al. Nat Med. 2020 Jul;26(7):992-994; (4) Caring for patients with cancer in the COVID-19 era. Van de Haar J et al. Nat Med. 2020 May;26(5):665-671; (5) New clinical trial designs in the era of precision medicine. Garralda E et al. Mol Oncol. 2019 Mar;13(3):549-557.

My personal interest is cancer research at all levels, but with special focus in Personalized Medicine and Scientific Management.

WIN is a very nice, challenging and unique example of international collaborative research, and has succeeded in allying academic and non-academic stakeholders to jointly develop pioneering proposals in Personalized Oncology. WIN completely converges with VHIO’s Vision of international collaborative research.